Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B/F/TAF in HIV-1 Patients with Active Substance Use
NCT03998176Phase 4Completed
- Sponsor
- University of Nebraska
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Nebraska. Started Oct 2019; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03998176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998176.